UNC Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients
July 31, 2024
This new study highlights safety and efficacy of Anti-CD30 CAR T-Cell therapy in high-risk lymphoma patients A team comprised mainly of faculty from the Division of Hematology and UNC Lineberger Comprehensive Cancer Center published a groundbreaking phase 1 study in The Lancet Haematology. The study demonstrates the safety and promising...